A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

In 'Diet, Drugs, and Dopamine,' former FDA Commissioner David A. Kessler offers a comprehensive guide to weight loss.

The surging popularity of hunger-suppressing weight-loss jabs, like Ozempic and Mounjaro, is having a slimming effect on ...

Ozempic is a glucagon-like peptide-1 receptor agonist, or GLP-1 medication. It’s only approved by the Food and Drug Administration (FDA) for treating type 2 diabetes, but with rising trends in ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that ...

Photo shows Illustration of a human silhouette with brain, injection pen and fast food. People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant ...

"If a Greek family starts a pizzeria, if a Chinese family straight from Beijing opens a hot dog shop, are they appropriating or are they just smart?" says the Food for Thought author and former Good ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO), opens new tab on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the ...

Experiencing coldness is a reported side effect of some GLP-1 medications, including Mounjaro and Ozempic. This is often attributed to reduced food intake and decreased thermogenesis (the body's ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss ... as well as the time of day when foods are eaten, the order that foods are eaten in, the speed of eating and even ...

Lars Fruergaard Jørgensen said he was “surprised” that the Ozempic-maker’s largest shareholder, the Novo Nordisk Foundation, had decided to remove him. “I did not see this coming,” he ...